

SLR:dm 4239-62631 156795.doc 12/04/02

KLARQUIST SPARKMAN, LLP

16th Floor World Trade Center, 121 S.W. Salmon Street, Portland, Oregon 97204 U.S.A.

PHONE: 503-226-7391 FAX: 503-228-9446

PLEASE DELIVER DIRECTLY TO EXAMINER CYBILLE DELACROIX-MUIRHEID**Fax No.:** (703) 746-5033**Total No. Pages:** 7 including this cover sheet**Message:** Transmitted herewith for filing in the above-identified application is an Amendment After Final Rejection. If you do not receive all pages or if you have problems receiving transmittal; please call Sheree Lynn Rybak, Ph.D. at (503) 226-7391. The fee (large entity) has been calculated as shown below.

In re application of: Liao et al.

Application No.: 09/634,369

Filed: August 9, 2000

For: ANTI-INFLAMMATORY ACTIONS OF
CYTOCHROME P450 EPOXYGENASE-DERIVED
EICOSANOIDS


Examiner: Cybille Delacroix-Muirheid

Art Unit: 1614

Date: December 4, 2002

CERTIFICATE OF FACSIMILE


I hereby certify that this correspondence and any documents referred to as being transmitted herewith are being facsimile transmitted to the Patent and Trademark Office via fax number (703) 746-5033 on December 4, 2002.


Agent for ApplicantsFEE CALCULATION FOR CLAIMS AS AMENDED

For	No. after amendment	No. paid for previously	Extra	Rate	Fee
Total Claims	9	- 32* =	0	\$18.00	\$0.00
Indep.	1	- 8** =	0	\$84.00	\$0.00
TOTAL FEE FOR THIS AMENDMENT					\$0.00

*greater of twenty or number for which fee has been paid. **greater of three or number for which fee has been paid.

- ☒ No additional fee is required.
- ☒ Please any additional fees that may be required in connection with filing of this Amendment After Final Rejection to Deposit Account 02-4550.


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913December 4, 2002
Date

cc: Docketing

THE INFORMATION CONTAINED IN THIS TRANSMISSION IS CONFIDENTIAL AND ONLY FOR THE INTENDED RECIPIENT IDENTIFIED ABOVE. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISSEMINATION OR USE OF THIS COMMUNICATION IS UNLAWFUL. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE (COLLECT), RETURN THE ORIGINAL MESSAGE TO US, AND RETAIN NO COPY.

SLR:slr:dm 12/4/02 154945.doc
PATENT

Attorney Reference Number 4239-62631
Application Number 09/634,369

#17/B
(C)
JRP
12/6/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Response Under 37 C.F.R. § 1.116 Expedited Procedure

In re application of: Liao et al.

Art Unit: 1614

Application No. 09/634,369

Filed: August 9, 2000


For: ANTI-INFLAMMATORY ACTIONS OF
CYTOCHROME P450 EPOXYGENASE-
DERIVED EICOSANOIDS

Examiner: Cybille Delacroix-Muirheid

Date: December 4, 2002

CERTIFICATE OF FACSIMILE

I hereby certify that this correspondence and any documents referred to as being transmitted herewith are being facsimile transmitted to the Patent and Trademark Office via fax number (703) 746-5033 on December 4, 2002.


Agent for Applicants

OK to
enter
CMM
BOX AF
COMMISSIONER FOR PATENTS
Washington, DC 20231

AMENDMENT AFTER FINAL REJECTION

This is an amendment and response to the final Office action dated October 22, 2002. A three-month period for response was set, making a response due on or before January 22, 2003.

In the claims:

28. (Reiterated) A method for preventing cell death from hypoxia-reoxygenation, comprising:
contacting a cell undergoing hypoxia reoxygenation with an effective amount of a composition of matter selected from the group consisting of epoxyeicosatrienoic acids (EETs), epoxyeicosatrienoic acid metabolic products, epoxyeicosatrienoic acid and dihydroxyeicosatrienoic acid analogs, and combinations thereof,

wherein the composition prevents cell death in the cell undergoing hypoxia-reoxygenation.

Please cancel claims 10-19, 21 and ~~25~~-27, without prejudice to prosecution in a future application.